With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. | With the ink barely dry on outgoing commissioner Marty ...
Doceree has bold ambitions to bring a new software category to pharma brand teams, one that reshapes campaign deployment in ...
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in ...
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ...
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...
Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is consolidating the workforce tied to the acquired company’s headquarters in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results